159 related articles for article (PubMed ID: 14722919)
41. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.
Prowse AH; Webster AR; Richards FM; Richard S; Olschwang S; Resche F; Affara NA; Maher ER
Am J Hum Genet; 1997 Apr; 60(4):765-71. PubMed ID: 9106522
[TBL] [Abstract][Full Text] [Related]
42. The von Hippel-Lindau tumour suppressor protein: new perspectives.
Ohh M; Kaelin WG
Mol Med Today; 1999 Jun; 5(6):257-63. PubMed ID: 10366821
[TBL] [Abstract][Full Text] [Related]
43. [Hippel-Lindau syndrome and sporadic renal cell carcinomas. Pathogenesis, morphologic spectrum and molecular genetics].
Brauch H; Böhm J; Höfler H
Pathologe; 1995 Sep; 16(5):321-7. PubMed ID: 7479604
[TBL] [Abstract][Full Text] [Related]
44. Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype.
Mettu P; Agrón E; Samtani S; Chew EY; Wong WT
Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4464-70. PubMed ID: 20375333
[TBL] [Abstract][Full Text] [Related]
45. The von Hippel-Lindau (VHL) germline mutation V84L manifests as early-onset bilateral pheochromocytoma.
Abbott MA; Nathanson KL; Nightingale S; Maher ER; Greenstein RM
Am J Med Genet A; 2006 Apr; 140(7):685-90. PubMed ID: 16502427
[TBL] [Abstract][Full Text] [Related]
46. Genotype-phenotype correlations in VHL exon deletions.
McNeill A; Rattenberry E; Barber R; Killick P; MacDonald F; Maher ER
Am J Med Genet A; 2009 Oct; 149A(10):2147-51. PubMed ID: 19764026
[TBL] [Abstract][Full Text] [Related]
47. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
[TBL] [Abstract][Full Text] [Related]
48. Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A.
Chen F; Slife L; Kishida T; Mulvihill J; Tisherman SE; Zbar B
J Med Genet; 1996 Aug; 33(8):716-7. PubMed ID: 8863170
[TBL] [Abstract][Full Text] [Related]
49. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.
Olschwang S; Richard S; Boisson C; Giraud S; Laurent-Puig P; Resche F; Thomas G
Hum Mutat; 1998; 12(6):424-30. PubMed ID: 9829912
[TBL] [Abstract][Full Text] [Related]
50. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.
Gorospe M; Egan JM; Zbar B; Lerman M; Geil L; Kuzmin I; Holbrook NJ
Mol Cell Biol; 1999 Feb; 19(2):1289-300. PubMed ID: 9891063
[TBL] [Abstract][Full Text] [Related]
51. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.
Whaley JM; Naglich J; Gelbert L; Hsia YE; Lamiell JM; Green JS; Collins D; Neumann HP; Laidlaw J; Li FP
Am J Hum Genet; 1994 Dec; 55(6):1092-102. PubMed ID: 7977367
[TBL] [Abstract][Full Text] [Related]
52. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
53. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis.
Forman JR; Worth CL; Bickerton GR; Eisen TG; Blundell TL
Proteins; 2009 Oct; 77(1):84-96. PubMed ID: 19408298
[TBL] [Abstract][Full Text] [Related]
54. Von Hippel-Lindau disease: clinical and molecular perspectives.
Clifford SC; Maher ER
Adv Cancer Res; 2001; 82():85-105. PubMed ID: 11447766
[TBL] [Abstract][Full Text] [Related]
55. Von Hippel-Lindau disease.
Maher ER
Curr Mol Med; 2004 Dec; 4(8):833-42. PubMed ID: 15579030
[TBL] [Abstract][Full Text] [Related]
56. Molecular analysis as a tool in the differential diagnosis of VHL disease-related tumors.
Gijtenbeek J; Jacobs B; Boots-Sprenger S; Bonne A; Lenders J; Küsters B; Wesseling P; Jeuken J
Diagn Mol Pathol; 2005 Jun; 14(2):115-20. PubMed ID: 15905696
[TBL] [Abstract][Full Text] [Related]
57. VHL2C phenotype in a German von Hippel-Lindau family with concurrent VHL germline mutations P81S and L188V.
Weirich G; Klein B; Wöhl T; Engelhardt D; Brauch H
J Clin Endocrinol Metab; 2002 Nov; 87(11):5241-6. PubMed ID: 12414898
[TBL] [Abstract][Full Text] [Related]
58. Molecular characterization and ophthalmic investigation of a large family with type 2A Von Hippel-Lindau Disease.
Allen RC; Webster AR; Sui R; Brown J; Taylor CM; Stone EM
Arch Ophthalmol; 2001 Nov; 119(11):1659-65. PubMed ID: 11709017
[TBL] [Abstract][Full Text] [Related]
59. Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH.
Decker HJ; Neuhaus C; Jauch A; Speicher M; Ried T; Bujard M; Brauch H; Störkel S; Stöckle M; Seliger B; Huber C
Hum Genet; 1996 Jun; 97(6):770-6. PubMed ID: 8641695
[TBL] [Abstract][Full Text] [Related]
60. Molecular genetic analysis of von Hippel-Lindau disease.
Richards FM; Webster AR; McMahon R; Woodward ER; Rose S; Maher ER
J Intern Med; 1998 Jun; 243(6):527-33. PubMed ID: 9681854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
